DK0954305T3 - Anvendelse af carbonanhydraseinhibitorer til behandling af maculaødem - Google Patents

Anvendelse af carbonanhydraseinhibitorer til behandling af maculaødem

Info

Publication number
DK0954305T3
DK0954305T3 DK97907822T DK97907822T DK0954305T3 DK 0954305 T3 DK0954305 T3 DK 0954305T3 DK 97907822 T DK97907822 T DK 97907822T DK 97907822 T DK97907822 T DK 97907822T DK 0954305 T3 DK0954305 T3 DK 0954305T3
Authority
DK
Denmark
Prior art keywords
carbonic anhydrase
treatment
macular edema
anhydrase inhibitors
cai
Prior art date
Application number
DK97907822T
Other languages
Danish (da)
English (en)
Inventor
Alon Harris
William Eric Sponsel
Original Assignee
Advanced Res & Tech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605642.9A external-priority patent/GB9605642D0/en
Application filed by Advanced Res & Tech Inst filed Critical Advanced Res & Tech Inst
Application granted granted Critical
Publication of DK0954305T3 publication Critical patent/DK0954305T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK97907822T 1996-02-26 1997-02-25 Anvendelse af carbonanhydraseinhibitorer til behandling af maculaødem DK0954305T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1225096P 1996-02-26 1996-02-26
GBGB9605642.9A GB9605642D0 (en) 1996-03-18 1996-03-18 Treatment of macular edema
PCT/US1997/002874 WO1997030704A2 (en) 1996-02-26 1997-02-25 Use of carbonic anhydrase inhibitors for treating macular edema

Publications (1)

Publication Number Publication Date
DK0954305T3 true DK0954305T3 (da) 2003-08-25

Family

ID=26308946

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97907822T DK0954305T3 (da) 1996-02-26 1997-02-25 Anvendelse af carbonanhydraseinhibitorer til behandling af maculaødem

Country Status (26)

Country Link
EP (1) EP0954305B9 (et)
JP (1) JP4392481B2 (et)
KR (1) KR100471586B1 (et)
CN (1) CN1225582A (et)
AT (1) ATE239468T1 (et)
AU (1) AU727565B2 (et)
BG (1) BG64525B1 (et)
BR (1) BR9707674A (et)
CA (1) CA2247063C (et)
CZ (1) CZ299509B6 (et)
DE (1) DE69721824T2 (et)
DK (1) DK0954305T3 (et)
EA (1) EA001681B1 (et)
EE (1) EE03804B1 (et)
ES (1) ES2199348T4 (et)
HU (1) HU227161B1 (et)
IL (1) IL125912A0 (et)
IS (1) IS2053B (et)
MX (1) MXPA98006961A (et)
NO (1) NO320043B1 (et)
NZ (1) NZ331843A (et)
PT (1) PT954305E (et)
SK (1) SK284371B6 (et)
TR (1) TR199801665T2 (et)
WO (1) WO1997030704A2 (et)
YU (1) YU49422B (et)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP1058546A4 (en) * 1998-03-06 2004-07-28 Univ Texas COMPILATIONS AND METHODS FOR THE TREATMENT OF MACULA DISEASES
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
JP2002520287A (ja) * 1998-07-10 2002-07-09 ザ・ユニバーシティ・オブ・シドニー 黄斑変性における血管新生の予防的治療
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20100063035A1 (en) 2006-12-15 2010-03-11 Nicox S.A. Carbonic anhydrase inhibitors derivatives
AR084194A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Derivados de arilsulfonamida para la prevencion o el tratamiento de trastornos oftalmologicos especificos
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
GB2223166B (en) * 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors

Also Published As

Publication number Publication date
DE69721824T2 (de) 2004-03-11
NO983906D0 (no) 1998-08-25
HUP9902054A3 (en) 2001-07-30
BR9707674A (pt) 2000-01-04
NO983906L (no) 1998-10-19
IS4829A (is) 1998-08-20
EP0954305B1 (en) 2003-05-07
EA001681B1 (ru) 2001-06-25
WO1997030704A2 (en) 1997-08-28
KR19990087242A (ko) 1999-12-15
DE69721824D1 (de) 2003-06-12
ES2199348T3 (es) 2004-02-16
CZ299509B6 (cs) 2008-08-20
IL125912A0 (en) 1999-04-11
TR199801665T2 (xx) 1998-12-21
NO320043B1 (no) 2005-10-17
HUP9902054A1 (hu) 2000-03-28
KR100471586B1 (ko) 2005-07-11
ATE239468T1 (de) 2003-05-15
MXPA98006961A (es) 2004-11-19
BG64525B1 (bg) 2005-06-30
CA2247063A1 (en) 1997-08-28
ES2199348T4 (es) 2010-10-19
BG102797A (en) 1999-09-30
EP0954305A2 (en) 1999-11-10
AU1972197A (en) 1997-09-10
JP2000506833A (ja) 2000-06-06
PT954305E (pt) 2003-09-30
NZ331843A (en) 2000-09-29
YU35398A (sh) 2001-12-26
WO1997030704A3 (en) 1997-09-25
EE9800263A (et) 1999-08-16
EP0954305B9 (en) 2010-08-04
HU227161B1 (en) 2010-09-28
CZ269998A3 (cs) 2000-01-12
SK284371B6 (sk) 2005-02-04
YU49422B (sh) 2006-01-16
EA199800764A1 (ru) 1999-06-24
CA2247063C (en) 2004-01-06
AU727565B2 (en) 2000-12-14
SK115198A3 (en) 2000-01-18
JP4392481B2 (ja) 2010-01-06
EE03804B1 (et) 2002-08-15
CN1225582A (zh) 1999-08-11
IS2053B (is) 2005-10-14

Similar Documents

Publication Publication Date Title
DK0954305T3 (da) Anvendelse af carbonanhydraseinhibitorer til behandling af maculaødem
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
DK0934061T3 (da) Isobutylgaba og dets derivater til behandling af smerte
DE69311101D1 (de) Verfahren sowie anordnung zum herstellen von wundverbänden sowie mit diesem verfahren hergestellter wundverband
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DK0514452T3 (da) Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
DK91793A (da) Fremgangsmåde til overfladebehandling, midler til udøvelse og anvendelsen heraf
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
UA66757C2 (en) Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
DK0642791T3 (da) Anvendelse af aminosyrer med forgrenet kæde til fremstilling af et lægemiddel til behandling af tardiv dyskinesi
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
DE69412178D1 (de) Apparat zur Behandlung von Lagen
DK0968174T3 (da) Optisk aktiv 2-aminotetralin, fremgangsmåde til dets fremstilling og farmaceutiske præparater indeholdende selv samme, effektiv til forebyggelse og behandling af septisk chok
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
NO984198L (no) FremgangsmÕte for behandling av aggresjon
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism
NO984190L (no) FremgangsmÕte for behandling av insomnia
RU94042315A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
AUPR204400A0 (en) Method and apparatus for the treatment of neoplastic growths